Pfizer-BioNTech COVID-19 vaccine overview and safety (also known as COMIRNATY)

Details

• Corporate Authors:
  National Center for Immunization and Respiratory Diseases (U.S.). Division of Viral Diseases.
• Description:
  Updated Sept. 28, 2021
  
  CDC now recommends that people aged 65 years and older, residents in long-term care settings, and people aged 50–64 years with underlying medical conditions should receive a booster shot of Pfizer-BioNTech’s COVID-19 Vaccine at least 6 months after completing their Pfizer-BioNTech primary series. Other groups may receive a booster shot based on their individual risk and benefit. Learn more.
  
  Cases of myocarditis and pericarditis in adolescents and young adults have been reported more often after getting the second dose than after the first dose of one of the two mRNA COVID-19 vaccines, Pfizer-BioNTech or Moderna. These reports are rare and the known and potential benefits of COVID-19 vaccination outweigh the known and potential risks, including the possible risk of myocarditis or pericarditis.
  
  
• Subjects:
  Coronavirus Infections/prevention & Control COVID-19 Vaccines COVID-19/prevention & Control Immunization, Secondary Viral Vaccines
• Document Type:
  Webpage
• Name as Subject:
  Pfizer-BioNTech COVID-19 Vaccine ; COMIRNATY
• Collection(s):
  Stephen B. Thacker CDC Library
• Main Document Checksum:
  urn:sha256:cc707ecb0bb6021fa0d54c3a0368be1f2a5bc49d0c064a0850eaf8a212567f20
• Download URL:
  https://stacks.cdc.gov/view/cdc/110115/cdc_110115_DS1.pdf
• File Type:
  [PDF - 615.42 KB ]